Bioequivalence Evaluation of a Folate-Supplemented Oral Contraceptive Containing Ethinylestradiol/Drospirenone/Levomefolate Calcium versus Ethinylestradiol/Drospirenone and Levomefolate Calcium Alone

被引：2
|
作者：
Herbert Wiesinger
Urte Eydeler
Frank Richard
Dietmar Trummer
Hartmut Blode
Beate Rohde
Konstanze Diefenbach
机构：
[1] Bayer HealthCare Pharmaceuticals,
[2] Scope International GmbH,undefined
[3] Nycomed GmbH — A Takeda Company,undefined
来源：
Clinical Drug Investigation | 2012年 / 32卷
关键词：
Folate; Folate Level; Folate Status; Study Drug Administration; Drospirenone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Neural tube defects (NTDs) are congenital malformations that occur during early embryonic development. Suboptimal maternal folate status is a well-known risk factor for the occurrence of NTDs, and periconceptional folic acid supplementation has been shown to reduce the risk of NTDs. Folate-supplemented oral contraceptives (OCs) offer a means of improving folate status in women of childbearing potential by increasing their likelihood of having raised folate levels at the time of conception.
引用
收藏
页码：673 / 684
页数：11
相关论文
共 30 条
123